Elsewhere, Ariad Pharmaceuticals ( ARIA) entered into a non-exclusive license agreement with cardiovascular device company Icon Medical, to develop and commercialize drug-eluting stents that deliver Ariad's novel mTOR inhibitor, deforolimus, to prevent re-narrowing of arteries after interventions in which stents are used with balloon angioplasty.

Icon is responsible for development and commercialization. Ariad is receiving an equity stake in Icon, up to $27 million in payments based on achievement of certain clinical, regulatory and commercial milestones for two products and royalties on all sales of Icon medical devices that deliver deforolimus. Additional terms weren't disclosed. Ariad shares edged down 12 cents, or 2.3%, to $5.01.

If you liked this article you might like

Stocks Mixed After Working on Railroad

Stocks Mixed After Working on Railroad

Stocks Log a Volatile Win

Stocks Log a Volatile Win

Stocks Get Spooked

Stocks Get Spooked

Dow's Gain: 199.89 as GDP Wows Wall Street

Dow's Gain: 199.89 as GDP Wows Wall Street

Stocks Trip Over Charts; Nasdaq Pummeled

Stocks Trip Over Charts; Nasdaq Pummeled